Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Use of the Bruininks-Oseretsky test of motor proficiency (BOT-2) to assess efficacy of velmanase alfa as enzyme therapy for alpha-mannosidosis

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Incidence of Aicardi-Goutières syndrome and KCNT1-related epilepsy in Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hearing loss in fabry disease: A 16 year follow-up study of the Danish nationwide cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Case report: ‘AARS2 leukodystrophy’

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Long-term follow-up of renal function in patients treated with migalastat for Fabry disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. von Hippel-Lindau disease: Updated guideline for diagnosis and surveillance

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Pyridoxine or pyridoxal-5-phosphate treatment for seizures in glycosylphosphatidylinositol deficiency: A cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Severe weight loss in a hypothyroid patient as an acute presentation of autoimmune polyglandular syndrome type II

    Research output: Contribution to journalReviewResearchpeer-review

  5. No effect of triheptanoin in patients with phosphofructokinase deficiency

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Dawn Phillips
  • Julia B Hennermann
  • Anna Tylki-Szymanska
  • Line Borgwardt
  • Mercedes Gil-Campos
  • Nathalie Guffon
  • Yasmina Amraoui
  • Silvia Geraci
  • Diego Ardigò
  • Federica Cattaneo
  • Allan M Lund
View graph of relations

Objectives: Alpha-mannosidosis is a rare autosomal recessive lysosomal storage disorder resulting from deficient lysosomal alpha-mannosidase activity. Clinical manifestations include progressive balance disorders, immune deficiency, skeletal abnormalities and cognitive deficits beginning in early childhood. Enzyme replacement therapy with recombinant human alpha-mannosidase (velmanase alfa) is scheduled for clinical development in the US beginning in 2020 and has been approved in the EU for treatment of non-neurological manifestations in cases of mild to moderate disease. This study assessed effects of velmanase alfa on fine and gross motor proficiency in children and adults.

Methods: Integrated Bruininks-Oseretsky (BOT-2) test of Motor Proficiency data from velmanase alfa clinical trials was stratified by age for 14 adults and 19 children treated for up to 4 years.

Results: Patients showed global developmental delays at baseline. For the combined adult and pediatric group there was a statistically significant increase (improvement) in BOT-2 total point score of 13% (p = .035, 95% CI 1.0, 25.0) from baseline to last observation. When stratified by pediatric versus adult patients, there was improvement in BOT-2 total point score in patients <18 years (mean percent increase from baseline to last observation 23%) compared to adults (mean decrease of -0.7%). Subtest analysis of individual BOT-2 items captured some improvement following velmanase alfa treatment in pediatric patients.

Conclusions: There was limited ability to assess the BOT-2 change responses in adults. Pediatric patients showed stability or improvement in scaled scores relative to healthy peers, indicating continued skill acquisition, which may increase independence and contribute to improved patient quality of life.

Original languageEnglish
JournalMolecular Genetics and Metabolism Reports
Volume23
Pages (from-to)100586
ISSN2214-4269
DOIs
Publication statusPublished - Jun 2020

ID: 62074560